Amsterdam - Delayed Quote EUR

Pharming Group N.V. (PHARM.AS)

0.8960

-0.0120

(-1.32%)

As of 4:39 PM GMT+2. Market Open.

Pharming Group to report first quarter 2024 financial results on May 8

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a un

GlobeNewswire 8 hours ago

PHAR

PHGUF
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare Impact Awards h

GlobeNewswire 9 hours ago

PHAR

PHGUF
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 days ago

PHARM.AS
-1.32%
URGN
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 19th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds due 2025 issued on 21

GlobeNewswire 4 days ago

PHAR

PHGUF
Pharming Group announces the placement of €100 million convertible bonds due 2029

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of th

GlobeNewswire 6 days ago

PHAR

PHGUF
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company"

GlobeNewswire 6 days ago

PHAR

PHGUF
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged

GlobeNewswire 16 days ago

PHAR

PHGUF
Pharming Group announces the 2024 Annual General Meeting of Shareholders

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The agenda of the AGM includes the reappointment of Ms. Barbara Y

GlobeNewswire 20 days ago

PHAR

PHGUF
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2023 Annual Report on Form 20

GlobeNewswire 20 days ago

PHAR

PHGUF
Pharming Group to participate in April investor conferences

Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April: 23rd Annual Needham Virtual Healthcare Conference, April 8-11, 2024Sijmen de Vries, Chief Executive Officer, will present on Monday, April 8 at 8:45ET/14:45CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections

GlobeNewswire 21 days ago

PHAR

PHGUF
Pharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Pharming Group N.V. ( AMS:PHARM ) came out with its yearly results last week, and we wanted to see how the business is...

Simply Wall St. last month

PHARM.AS
-1.32%
Pharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group ( AMS:PHARM ) Full Year 2023 Results Key Financial Results Revenue: US$245.3m (up 19% from FY 2022). Net...

Simply Wall St. last month

PHARM.AS
-1.32%
Pharming Group reports fourth quarter and full year 2023 financial results

Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 millionStrong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 millionOverall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end of 202

GlobeNewswire last month

PHAR

PHGUF
Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.To participate in the conference call, please register in advance using the link below. Once registered, dial-

GlobeNewswire last month

PHAR

PHGUF
Pharming Group to participate in February investor conferences

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of February: Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference, February 13-14, 2024Sijmen de Vries, Chief Executive Officer, will present on Tuesday, February 13 at 11:20 ET/17:20 CET. A live webcast and replay of the presentation will be available in the “Up

GlobeNewswire 2 months ago

PHAR

PHGUF
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the full year 2023

GlobeNewswire 3 months ago

PHAR

PHGUF
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming has engaged wit

GlobeNewswire 4 months ago

PHAR

PHGUF
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective p

GlobeNewswire 5 months ago

PHAR

PHGUF
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetab

GlobeNewswire 5 months ago

PHAR

PHGUF
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November. IPIC, Rotterdam, The Netherlands, November 8 - 10, 2023 Approaches to family testing for auto

GlobeNewswire 5 months ago

PHAR

PHGUF

Performance Overview

Return	PHARM.AS	AEX-Index
YTD	-13.09%	+11.37%
1-Year	-8.10%	+14.97%
3-Year	-15.03%	+22.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pharming Group N.V. (PHARM.AS)

Pharming Group to report first quarter 2024 financial results on May 8

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Pharming Group announces the placement of €100 million convertible bonds due 2029

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Pharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Pharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group reports fourth quarter and full year 2023 financial results

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Pharming Group to participate in February investor conferences

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Performance Overview